Rexin-G, a targeted genetic medicine for cancer

Expert Opinion on Biological Therapy

Volumn 10, Issue 5, 2010, Pages 819-832

  Gordon, Erlinda M ^a   Hall, Frederick L ^a  

^a Epeius Biotechnologies Corporation   (United States)

Author keywords

Cancer therapy; Cell cycle control; Cyclin G1; Gene therapy; Genetic medicine; Nanomedicine; Osteosarcoma; Pancreas cancer; Pathotropic targeting; Sarcoma; Targeted gene delivery

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CISPLATIN; DACARBAZINE; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; GENE THERAPY AGENT; IFOSFAMIDE; METHOTREXATE; REXIN G; UNCLASSIFIED DRUG;

BIOENGINEERING; CANCER INHIBITION; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; FATIGUE; GENE DELIVERY SYSTEM; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; OSTEOSARCOMA; PANCREAS CANCER; PHOTOPHOBIA; PRESYNCOPE; REVIEW; SOFT TISSUE SARCOMA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; CYCLIN G1; EVIDENCE-BASED MEDICINE; GENE THERAPY; GENETIC VECTORS; HUMANS; MUTATION; NEOPLASMS; TREATMENT OUTCOME;

EID: 77951123789     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.481666     Document Type: Review

References (56)

1. Retrovector encoding mutant anti-cyclin G1 (Code C49082). NCI thesaurus http://ncit.nci.nih.gov/ncitbrowser/ ConceptReport.jsp?dictionary=NCI% 20Thesaurus&code=C49082
2. Hall FL, Gordon EM, Wu L, et al. Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMuLV gp70 envelope protein. Hum Gene Ther 1997;10:2183-2192
3. Hall FL, Liu L, Zhu NL, et al. Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor. Hum Gene Ther 2000;11:983-993
4. Gordon EM, Liu PX, Zhen ZH, et al. Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct. Cancer Res 2000;60:3343-3347
5. Gordon EM, Liu PX, Chen ZH, et al. Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice. Hum Gene Ther 2001;12:193-204
6. Chawla SP, Chua VS, Fernandez L, et al. Phase I/II and Phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy- resistant osteosarcoma and other sarcomas. Mol Ther 2009;17(9):1651-1657
7. Chawla SP, Chua VS, Fernandez L, et al. Advanced Phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer. Mol Ther 2010;18:435-441
8. Surveillance, Epidemiology, and End Results (SEER) Program (2008). Prevalence database: "US estimated 29-year LD counts on prevalence on 1/1/ 2004 by duration" for Bones and Joints Cancer. National Cancer Institute, DCCPS, Surveillance Research Program, Statistical Research and Applications Branch, based on the November 2008 SEER data submission. www.seer.cancer.gov
9. Longhi A, Errani C, De Paolis M, et al. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006;32:423-426
10. Kempf-Bielack B, Bielack SS, Jurgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the cooperative osteosarcoma study group (COSS). J Clin Oncol 2005;23:559-568
11. Surveillance, Epidemiology, and End Results (SEER) Program (2008). Prevalence database: "US estimated 29-year LD counts on prevalence on 1/1/2004 by duration" for Soft Tissue including Heart Cancer. National Cancer Institute, DCCPS, Surveillance Research Program, Statistical Research and Applications Branch, based on the November 2008 SEER data submission. www.seer.cancer.gov
12. Milano A, Apice G, Ferrari E, et al. New emerging drugs in soft tissue sarcoma. Crit Rev Oncol Hematol 2006;59:74-84
13. Mocellin S, Rossi CR, Brandes A, Nitti D. Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer Treat Rev 2006;32:9-27
14. Geer RJ, Woodruff J, Casper ES, Brennan MF. Management of small soft-tissue sarcoma of the extremity in adults. Arch Surg 1992;127:1285-1289
15. Karakousis CP, Sografos GC. Radiation therapy for high grade soft tissue sarcomas of the extremities treated with limb-preserving surgery. Eur J Surg Oncol 2002;28:431-436
16. Cormier JN, Pollock RE. Soft tissue sarcomas. J Clin Oncol 2004;54:94-109
17. Dileo P, Demetri GD. Update on new diagnostic and therapeutic approaches for sarcomas. Clin Adv Hematol Oncol 2005;3:781-791
18. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival -- a report from the Children's Oncology Group. J Clin Oncol 2008;26:633-638
19. Mori K, Redini F, Gouin F, et al. Osteosarcoma: current status of immunotherapy and future trends (Review). Oncol Reports 2006;15:693-700
20. Witlox MA, Lamfers ML, Wuisman PI, et al. Evolving gene therapy approaches for osteosarcoma using viral vectors: review. Bone 2007;40:797-812
21. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009;59:111-137
22. Fayette J, Boyle H, Chabaud S, et al. Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution. Anticancer Drugs 2010:21:113-119
23. American Cancer Society, Cancer Facts and Figures 2008 (2007). Atlanta GA: American Cancer Society 2009:16-17
24. Nieto J, Grossbard ML, Kozuch P. Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist 2008;13:562-576
25. Burris HA 3rd, Moore JM, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413
26. Burris H 3rd, Rocha-Lima C. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 2008;13:289-298
27. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;24:1960-1966
28. Senderowicz AM, Johnson JR, Sridhara R, et al. Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology 2007;21:1696-1706
29. Almhanna K, Kim R. Second-line therapy for gemcitabine-refractory pancreatic cancer: Is there a standard? Oncology 2008;22:1176-1183
30. Wu L, Liu L, Yee A, et al. Molecular cloning of the human CYCG1 gene encoding a G-type cyclin: overexpression in osteosarcoma cells. Oncol Rep 1994;1:705-711
31. Skotzko MJ, Wu LT, Anderson WF, et al. Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Res 1995;55:5493-5498
32. Gordon EM, Hall FL. The 'timely' development of Rexin-G: first targeted injectable gene vector (Review). Int J Oncol 2009;35:229-238
33. Reimer CL, Borras AM, Kurdistani SK, et al. Altered regulation of cyclin G1 in human breast cancer and its specific localization at replication foci in response to DNA damage in p53+/+ cells. J Biol Chem 1999;274:11022-11029
34. Perez R, Wu N, Lipfel AA, Beart RW Jr. A better cell cycle target for gene therapy for colorectal cancer: cyclin G. J Gastrointest Surg 2003;7:884-889
35. Gramantieri L, Ferracin M, Formari F, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007;67:6092-6099
36. Xu F, Prescott MF, Liu PX, et al. Long term inhibition of neointima formation in balloon-injured rat arteries by intraluminal instillation of a matrix-targeted retroviral vector bearing a cytocidal mutant cyclin G1 construct. Int J Mol Med 2001;8:19-30
37. Gordon EM, Chan MT, Geraldino N, et al. Le morte du tumour: Histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes. Int J Oncol 2007;30:1297-1307
38. Lenz H-J, Anderson WF, Hall FL, Gordon EM. Clinical protocol: tumor site specific Phase I evaluation of safety and efficacy of hepatic arterial infusion of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct as intervention for colorectal carcinoma metastatic to liver. Hum Gene Ther 2002;3:1515-1537
39. Galanis E, Carlson SK, Foster NR, et al. Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer. Molecular Ther 2008;16:979-984
40. Gordon EM, Cornelio GH, Lorenzo CC 3rd, et al. First clinical experience using a "pathotropic" injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. Int J Oncol 2004;24:177-185
41. Gordon EM, Lopez FF, Cornelio GH, et al. Pathotropic nanoparticles for cancer gene therapy. Rexin-G IV: three-year clinical experience. Int J Oncol 2006;29:1053-1064
42. Storer BE. Design and analysis of phase I clinical trials. Biometrics 1989;45:925-937
43. Gordon EM, Levy JP, Reed RA, et al. Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ. Int J Oncol 2008;33:665-675
44. Hirschfeld A, Pazdur R. Oncology drug development: United States Food and Drug Administration perspective. Crit Rev Oncol Hematol 2002;42:137-143
45. Gordon EM, Hall FL. A primer on pathotropic medicine. In celebrating one hundred years of the Food and Drug Administration. A Special Centennial Edition. Brooklands New Media LTD, Oswestry, Shropshire, UK; 2007. p. 80-83
46. Gordon EM, Hall FL. Nanotechnology blooms, at last (Review). Oncol Reports 2005;13:1003-1007
47. Gordon EM, Hall FL, Beart RW Jr, Anderson WF. Genetic engineering of targeted retroviral vectors. In vector targeting for therapeutic gene delivery. Curiel DT, Douglas JT, editors, Wiley-Liss, Inc., New Jersey, USA; 2002. p. 293-320
48. FDA: Critical Path Opportunities List. U.S. DHHS, FDA, March 2006, www.fda.gove/oc/initiative/criticalpath/
49. Abeloff MD. Perspective: new endpoints needed in targeted Rx trials. Oncol News Int'l 2006;15:2-16
50. Therasse P, Arbuck SC, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-210
51. Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic measurements of tumor response to treatment: Practical approaches and limitations. RadioGraphics 2008;28:329-344
52. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25:1760-1764
53. Schuetze SM, Baker LH, Benjamine RS, Canetta R. Selection of response criteria for clinical trials of sarcoma treatment. The Oncologist 2008;13(Suppl 2):32-40
54. Desar IME, van Herpen CML, van Laarhoven HWM, et al. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treatment Reviews 2009;35:309-321
55. Chen DS, Zhu NL, Hung G, et al. Retroviral vector-mediated transfer of an antisense cyclin G1 construct inhibits osteosarcoma tumor growth in nude mice. Hum Gene Ther 1997;8:1679-1686
56. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007;8:573-587